InMed Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is July - June.

Millions USD. Fiscal year is Jul - Jun.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 25, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Market Cap	7	7	2	62	153	512
Market Cap Growth	97.15%	174.82%	-96.16%	-59.65%	-70.14%	-
Enterprise Value	2.14	-3.87	-3.28	53.14	147.48	504.89
Last Close Price	1.53	3.25	5.31	18.54	235.00	1590.00
PS Ratio	1.40	1.32	0.51	14.92	140.35	-
PB Ratio	0.75	0.48	0.26	5.10	16.84	69.41
P/TBV Ratio	0.95	0.27	0.27	0.22	0.95	3.38
EV/Sales Ratio	0.43	-0.78	-0.71	12.85	135.37	-
EV/EBITDA Ratio	-	0.52	0.43	-	-	-
EV/EBIT Ratio	-	0.49	0.40	-	-	-
EV/FCF Ratio	-	0.50	0.47	-	-	-
Debt / Equity Ratio	0.00	0.02	0.07	0.00	0.04	0.03
Net Debt / Equity Ratio	-0.69	-0.77	-0.61	-0.71	-0.60	-0.97
Net Debt / EBITDA Ratio	0.58	1.40	0.74	1.09	0.32	0.74
Net Debt / FCF Ratio	0.64	1.34	0.81	1.15	0.35	0.73
Asset Turnover	0.32	0.36	0.35	0.31	0.10	0
Inventory Turnover	4.77	2.93	2.44	1.33	0.44	-
Quick Ratio	2.35	6.30	3.53	4.61	1.90	3.35
Current Ratio	3.11	6.99	4.41	5.66	2.89	3.78
Return on Equity (ROE)	-33.88%	-72.10%	-71.95%	-74.84%	-226.07%	-153.95%
Return on Assets (ROA)	-86.45%	-58.00%	-63.16%	-62.56%	-152.99%	-113.04%
Return on Invested Capital (ROIC)	-267.53%	-237.12%	-230.84%	-218.77%	-612.86%	-653.29%
Return on Capital Employed (ROCE)	-105.63%	-67.37%	-74.66%	-78.12%	-202.71%	-145.17%
Buyback Yield / Dilution	-365.07%	-156.13%	-211.26%	-336.58%	-108.65%	-28.72%
Total Shareholder Return	-365.07%	-156.13%	-211.26%	-336.58%	-108.65%	-28.72%

SEC Filings: 10-K · 10-Q